Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19092135 | 0.83 | USP2 (0.46) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL13408078 | 0.83 | USP2 (0.46) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL3616096 | 0.83 | USP2 (0.46) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL14823741 | 0.82 | HPGD (0.54) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL15918769 | 0.82 | HPGD (0.54) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL3616091 | 0.81 | USP2 (0.45) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL3616093 | 0.81 | USP2 (0.45) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL15863855 | 0.80 | USP2 (0.44) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL16370880 | 0.80 | USP2 (0.44) | USP2SMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL12697881 | 0.80 | USP2 (0.44) | USP2SMN1; SMN2HPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169260-B2 | Amidopyrazole inhibitors of interleukin receptor-associated kinases | MERCK SHARP & DOHME CORP. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140194404-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | MERCK SHARP & DOHME LLC | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194404-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | IRAK4, IRAK3, IRAK1 | USP2 3104/4885SMN1; SMN2 4195/4885HPGD 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.